CA2443950C — Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas

USPTO Abstract

This invention relates to a group of quinolyl, isoquinolyl and pyridyl ureas, their use in treating raf mediated diseases, and pharmaceutical compositions which contain these ureas for use in such therapy. These compounds have one of the following formulae: A D B (I) A'-D-B' (II) A"~D~B" (III) wherein D is -NH-C (O)-NH-; A is a substituted pyridyl group; A' is an optionally substituted isoquinolinyl group or a quinolinyl group; A" is a substituted quinolinyl group, B and B' are each, independently, a substituted or unsubstituted bridged cyclic structure of up to 30 carbon atoms; and a cyclic moiety having at least members and B" is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms.